|
|
||||||||

* Section of Endocrinology, Department of Medicine, and
Department of Physiology, Louisiana State University Medical Center, New Orleans, Louisiana 70112
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
There is no question that leptin plays a role in many forms of obesity in animals (12). The realization that a hormone and its receptor can regulate body weight makes obesity an endocrine disorder (13). Other hormones interact with leptin, such as insulin (14-16) and glucocorticoids (17, 18). The adrenal hormone dehydroepiandrosterone (DHEA) has antiglucocorticoid effects (19). Administration of DHEA to Zucker rats has been shown to decrease insulin levels (20-22), decrease intra-abdominal fat pad mass (9, 22-25), and result in less body weight either through weight loss in fully grown rats (9, 21) or less weight gain in growing rats (21-25). Since body fat mass, insulin, and glucocorticoids interact with peripheral leptin levels, we wondered whether DHEA administration would also affect leptin levels in Zucker rats. One would expect lower leptin levels simply because of the smaller fat pads that result from DHEA administration, but the defective leptin receptor may interfere with this expected drop (26, 27). In this study, the effects of DHEA on intra-abdominal fat pad mass, serum lipids, insulin, corticosterone, and peripheral leptin were investigated in young male Zucker rats given DHEA over a prolonged period.
| Materials and Methods |
|---|
|
|
|---|
A group of male obese Zucker rats (n = 6) were also randomly chosen from the colony at 4 weeks of age and handled in the same manner as described above with the exception of their diet. Briefly, these calorie-restricted, pair-fed animals were fed an amount of powdered rat chow matching the weekly historical mean amount of food consumed by the DHEA-treated obese rats.
All of these rats were housed individually in group-sized, hanging wire-mesh cages and had unlimited access to water. Except for the pair-fed rats, they had unlimited access to food as well. When the earlier studies had been completed, additional control groups, referred to as the weight-matched controls, were selected from the colony based on body weight. The heterozygous lean rats in the colony were weighed, and six animals were chosen randomly from among those that had body weights that were similar to the final body weights of the lean rats treated with DHEA. In like manner, six obese rats were also chosen randomly from among those having a body weight similar to the final weight of the obese rats treated with DHEA. These weight-matched rats were necessarily younger than the lean and obese controls (lean 9.6 ± 0.0, obese 11.1 ± 0.5 weeks of age) and were also sacrificed by decapitation after being fasted. Prior to being chosen for this protocol, these additional weight-matched controls had shared group-sized, hanging wire-mesh cages with unlimited access to food and water. Their food consumption was not monitored.
Determination of serum triglycerides and total cholesterol was performed by standard automated laboratory techniques using the Paramax 720ZX Automated Chemistry Analyzer (Baxter Healthcare Corp., Paramax Systems Division, Irvine, CA). Serum leptin and insulin were measured with commercially available radioimmunoassay kits specific for rat leptin and rat insulin, respectively (Linco Research, Inc., St. Charles, MO). Serum DHEA-S and corticosterone were measured with commercially available radioimmunoassay kits (Diagnostic Laboratories, Inc., Webster, TX). Serum content of nonesterified (free) fatty acids (FFA) was determined using a commercially available enzymatic colorimetric kit (Wako Chemicals USA, Inc., Richmond, VA). Because the younger, weight-matched animals were added at the end of the experiment after the corticosterone assay was completed, serum corticosterone levels were not determined in the weight-matched animals. In addition, only two specimens from the obese pair-fed group were available for the corticosterone assay due to a laboratory error.
All animals were treated humanely under the guidelines of the National Institutes of Health and the Animal Welfare Act. The protocol for this experiment was approved by the LSU Medical Center Institutional Animal Care and Use Committee (IACUC).
All results are listed as mean ± SEM where appropriate. Results were analyzed with JMP version 3.1.6.2 statistical software (SAS Corp., Cary, NC). The continuous data were analyzed by two-way ANOVA using the "Fit Model" routine with phenotype, diet, and phenotype x diet as independent variables. A P-value < 0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
Compared with the age-matched controls, the total intra-abdominal fat pad mass was decreased in the DHEA-treated groups and in the weight-matched control groups of both phenotypes whereas the total intra-abdominal fat pad mass of the lean and obese weight-matched controls was similar to that of the lean and obese DHEA-treated rats, respectively. The group of obese pair-fed rats had a total intra-abdominal fat pad mass that was smaller than that of the obese age-matched controls, but larger than that of both the DHEA-treated rats and the weight-matched controls. With only a few exceptions, the same patterns were evident when examining the individual epididymal, perinephric, and retroperitoneal intra-abdominal fat pads. The intra-abdominal fat pad weights expressed as a percentage of total body weight also exhibited similar relationships as the absolute fat pad weights.
Glucose, Insulin, and Corticosterone.
In the lean rats, serum glucose was increased with administration of DHEA compared with the age-matched controls. The obese weight-matched controls had lower serum concentrations of glucose than did any other group of obese rats. The obese pair-fed group had a higher glucose level than any of the other obese groups. All of the lean groups had lower glucose levels than their obese counterparts.
Insulin levels were markedly elevated in all of the obese groups compared with their lean counterparts. DHEA treatment reduced insulin levels in the obese rats, but not in the lean rats. Pair feeding the obese rats did not change the insulin levels compared with either the age-matched controls or the DHEA-treated obese rats. The obese weight-matched controls had lower insulin levels than the other obese groups. Among the lean rats, the insulin level was unchanged in either the DHEA-treated or weight-matched controls.
Corticosterone levels were increased by DHEA administration to the lean rats. The obese rats showed no effect from DHEA.
Lipids and FFA.
Total cholesterol and triglycerides were lower in each lean group than in the corresponding obese group except for triglycerides that were nearly different (P < 0.06) in the weight-matched control groups. The obese weight-matched controls had lower levels of total cholesterol and triglycerides than their respective age-matched controls. DHEA treatment in the obese rats reduced the total cholesterol and triglyceride levels compared with their age-matched controls. In the lean rats, DHEA treatment had no effect on either triglycerides or total cholesterol. Pair-feeding the obese rats lowered total cholesterol but not triglycerides, when compared with the obese age-matched controls.
Compared with the lean age-matched controls, FFA levels were unaffected by DHEA administration to lean rats and unchanged in the lean weight-matched controls. The FFA levels of each lean group were less than those of their obese counterparts. Among the obese rats, FFA levels were lowered similarly in both the DHEA-treated and weight-matched control groups compared with both the age-matched controls and the pair-fed groups that also exhibited similar levels.
Leptin.
Leptin levels were markedly increased in all obese groups compared with any lean group whereas the lean groups all had similar leptin levels. Among the obese rats, DHEA treatment lowered leptin levels compared with those of the obese age-matched controls. The obese weight-matched controls had higher leptin levels than any other group. The pair-fed group had leptin levels that were similar to those of the age-matched controls.
| Discussion |
|---|
|
|
|---|
DHEA given chronically to lean or obese Zucker rats results in decreased body weights, intra-abdominal fat pad weights, and insulin concentrations (30). The investigation being reported here also showed decreased body weights and intra-abdominal fat pad weights in lean and obese Zucker rats, along with decreased insulin levels in obese Zucker rats. In the DHEA-treated obese rats, the reduction in fat pad weight may be the main reason that leptin levels fell, but the reduction in insulin may also have contributed because insulin can stimulate leptin production in normal rodents (3, 26). However, glucocorticoids can increase leptin production (18), and corticosterone, a glucocorticoid, was increased with DHEA administration in the lean rats. The lean weight-matched controls also had reduced fat pads, but only a trend toward lower insulin and leptin.
Another way of analyzing leptin levels is with the ratio of leptin-to-fat pad weight (31). If leptin expression were solely controlled by adiposity, this ratio should be constant. The ratio was similar among the lean groups whereas each obese group had a different ratio. In fact, a possible age-effect was demonstrated by the fact that the obese weight-matched controls, though younger than the age-matched controls, had lower body weights and less intra-abdominal fat, but greater leptin-to-total fat pad weights. DHEA-treatment and pair-feeding the obese rats also decreased body weights and intra-abdominal fat pad weights while increasing the ratio to intermediate values compared with the age-matched controls. The data presented here do not allow the determination of whether DHEA exerted an independent effect on leptin levels or an indirect effect by leading to lower body weights. However, in contrast to the lean rats, the obese DHEA-treated rats had reduced fat pad weights but with only slightly reduced leptin levels and no change in corticosterone or insulin levels. The unexpectedly small change in leptin levels exhibited by the obese rats associated with marked reductions in intra-abdominal body fat could be due to the impaired leptin receptor because leptin receptors are apparently required for the downregulation of leptin expression (26, 27), but could DHEA also play a role? By controlling for the decreased caloric intake that results from DHEA administration, the obese pair-fed group showed that less food intake could explain some of the reductions in body weight and intra-abdominal fat pad weights of the DHEA-treated obese rats, but the pair-fed rats had no change, compared with age-matched controls, in leptin, triglycerides, insulin, or corticosterone despite their reductions in body and fat pad weights due to caloric restriction, whereas DHEA-treatment reduced leptin, triglycerides, total cholesterol, and insulin, compared with the same age-matched controls. It is interesting that food restriction alone does not prevent the development of obesity in obese Zucker rats (11) and that the pair-fed group weighed more than the DHEA-treated group and had larger fat pads. These results support the view of some researchers that DHEA exerts an independent effect on body weight and fat pad weights beyond that of a reduced caloric intake (20, 24, 32). To help control for this observation, the obese weight-matched controls were added to the study and showed no differences in intra-abdominal fat pad weights compared with the obese DHEA-treated rats, but insulin and triglyceride levels were higher. It is further interesting that these weight-matched obese controls actually had higher leptin levels than any other group and that these higher leptin levels occurred in rats with lower body weight, fat pad weights, and insulin levels than the obese age-matched controls. However, it must be emphasized that the lean and obese weight-matched groups were necessarily younger in age and that this age difference could indicate different levels of sexual maturity that could alter hormone levels.
The purpose of this study was to investigate the effect of DHEA on leptin levels. In the lean Zucker rats, DHEA administration did not exert any significant changes in leptin or insulin levels despite a reduction in caloric intake, body weight, and total intra-abdominal fat pad weight, though the leptin levels did tend to be lower. However, the effects of DHEA in obese Zucker rats were more complicated. Chronic DHEA administration to obese Zucker rats reduced total caloric intake, body weight, and total intra-abdominal fat pad weight to a greater degree than would be expected from the DHEA-associated reduction in caloric intake based on the pair-fed group, implying an independent effect on body weight and fat pad weights. Despite this very marked reduction in body weight and total fat pad weight with both DHEA treatment and pair-feeding, the leptin levels did not drop to any great degree. Why this is so is not clear at this time. Although leptin is produced by adipocytes and is a marker of adipose tissue mass (28, 29), this investigation shows that serum leptin levels do not depend solely upon adipose tissue mass and insulin levels in the obese Zucker rat. Furthermore, if duplicated in other studies, the observation that the younger, weight-matched obese rats had higher leptin levels than the obese controls, despite less body weight and total intra-abdominal fat pad weight, may indicate an age and/or maturity relationship to leptin levels in obese Zucker rats.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 To whom requests for reprints should be addressed at LSU Medical Center, Department of Medicine, Section of Endocrinology, 1542 Tulane Ave., New Orleans, LA 701122822. E-mail: richards{at}lsumc.edu ![]()
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Kajita, T. Ishizuka, T. Mune, A. Miura, M. Ishizawa, Y. Kanoh, Y. Kawai, Y. Natsume, and K. Yasuda Dehydroepiandrosterone Down-Regulates the Expression of Peroxisome Proliferator-Activated Receptor {gamma} in Adipocytes Endocrinology, January 1, 2003; 144(1): 253 - 259. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |